Drug Trial Radar · NCT04765553
A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.
Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 14, 2021
Primary completion
Jun 25, 2021
Study completion Jul 25, 2021
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (care provider)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, placebo controlled and double-blinded study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of a single dose (1 mg/kg) of emapalumab in adult healthy Japanese subjects.
Conditions
- Rare Diseases
Interventions
NI-0501Drug
emapalumab single i.v infusion (1 mg/kg)
SalineDrug
Saline single i.v infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Maximum Observed Concentration of EmapalumabTime frame: Day 1 preinfusion, 1hr, 2hrs, 4hrs, 8hrs, 10hrs post dose, day 2, 3, 5, 8, week 2, 4, 6, 8, 10, 12, study completion week 14 or Withdrawal
- The Time at Which the Maximum Concentration of Emapalumab is ObservedTime frame: Day 1 preinfusion, 1hr, 2 hrs, 4hrs, 8hrs, 10hrs, Day 2, 3, 5, 8, Week 2, 4, 6, 8, 10, 12, study completion week 14 or at Withdrawal
- Concentration of Emapalumab at End of InfusionTime frame: Day 1 preinfusion, 1hr, 2 hrs, 4hrs, 8hrs, 10hrs, Day 2, 3, 5, 8, Week 2, 4, 6, 8, 10, 12, study completion week 14 or at Withdrawal
- Area Under the Plasma Concentration-time CurveTime frame: Day 1 preinfusion, 1hr, 2 hrs, 4hrs, 8hrs, 10hrs, Day 2, 3, 5, 8, Week 2, 4, 6, 8, 10, 12, study completion week 14 or at Withdrawal
- Area Under the Concentration-time Curve Extrapolated to InfinityTime frame: Day 1 preinfusion, 1hr, 2 hrs, 4hrs, 8hrs, 10hrs, Day 2, 3, 5, 8, Week 2, 4, 6, 8, 10, 12, study completion week 14 or at Withdrawal
- Emapalumab Elimination Half-lifeTime frame: Day 1 preinfusion, 1hr, 2 hrs, 4hrs, 8hrs, 10hrs, Day 2, 3, 5, 8, Week 2, 4, 6, 8, 10, 12, study completion week 14 or at Withdrawal
- Apparent Total Body Clearance of Emapalumab From PlasmaTime frame: Day 1 preinfusion, 1hr, 2 hrs, 4hrs, 8hrs, 10hrs, Day 2, 3, 5, 8, Week 2, 4, 6, 8, 10, 12, study completion week 14 or at Withdrawal
- Steady State Volume of DistributionTime frame: Day 1 preinfusion, 1hr, 2 hrs, 4hrs, 8hrs, 10hrs, Day 2, 3, 5, 8, Week 2, 4, 6, 8, 10, 12, study completion week 14 or at Withdrawal
Locations
1 site in 1 country. Site status is shown where the registry gives one.
P-One Clinic
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.